2026年英国风湿病学会炎症性关节炎疼痛管理指南
该指南由英国风湿病学会多学科工作组制定,针对炎症性关节炎(IA)患者的疼痛管理提出23条循证推荐。指南涵盖疼痛评估及DMARDs、糖皮质激素、镇痛药、运动、心理干预等多种治疗的作用,并指出英国实践中长期使用阿片类和加巴喷丁类药物缺乏证据支持,而有效非药物干预使用不足。
要点
- 指南提供23条推荐,涵盖疼痛评估及药物与非药物治疗。
- 英国IA患者疼痛管理常长期使用阿片类和加巴喷丁类药物,缺乏疗效证据。
- 有支持证据的非药物疼痛干预在临床中使用不足。
核心结论
- 指南为炎症性关节炎患者疼痛管理提供循证推荐,共23条,并附审计工具支持实施。
研究设计与样本
- 由英国风湿病学会多学科指南工作组依据其「创建临床指南」方案制定,成员包括儿童和成人风湿病专家及有亲身经历者。
主要发现
- 电子健康记录分析显示英国IA患者疼痛护理常涉及长期处方阿片类和加巴喷丁类药物,但缺乏疗效试验证据。
- 患者调查数据显示有支持证据的非药物疼痛护理使用不足。
关键数值与推荐
- 通过多项系统文献综述和伞状综述形成23条推荐,涵盖疼痛评估及DMARDs、糖皮质激素、镇痛药、神经调节剂、运动与体力活动、心理干预、人体工效学与矫形器(足痛矫形器除外)、教育、体重管理与饮食、睡眠问题、疲劳管理、数字技术与医疗设备、补充疗法及他人支持的作用。
临床怎么用
- 指南推荐应基于证据评估和管理IA疼痛,避免无证据支持的长期阿片类和加巴喷丁类药物处方,并加强有证据的非药物干预使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pain is a frequent symptom in people with inflammatory arthritis (IA), which has substantial impact on their quality of life. Analyses of electronic health record data indicate that UK pain care in people with IA often involves prescribing long-term opioids and gabapentinoids, despite absent trial evidence for efficacy. Patient survey data suggest that non-pharmacological pain care with supportive trial evidence is underused. A UK-specific guideline on pain management for people with IA is required to address this. This comprehensive life-course guideline is the first British Society for Rheumatology Guideline to specifically address pain in people with IA. It provides evidence-based recommendations on how pain can be best managed in people with IA. It was developed using the methods outlined in the British Society for Rheumatology's 'Creating Clinical Guidelines' protocol by a multidisciplinary Guideline Working Group, comprising healthcare professionals with expertise in paediatric and adult rheumatology and people with lived experience. By undertaking and considering the evidence from several systematic literature and umbrella reviews, 23 recommendations were developed. These address how pain should be assessed in people with IA alongside the role of the following treatments in IA pain management: DMARDs, glucocorticoids, analgesics, neuromodulators, exercise and physical activity, psychological interventions, ergonomic and orthotic interventions (excluding orthoses for foot pain), education, weight management and diet, addressing sleep problems, fatigue management, digital technologies and medical devices, complementary therapies, and support from others. An audit tool is provided to support the Guideline's implementation, and key recommendations made for future research.
引用
- Scott IC, Smith TM, Babatunde O, et al. The 2026 British Society for Rheumatology guideline for pain management in people with inflammatory arthritis. Rheumatology (Oxford). 2026. PMID: 42476581. doi:10.1093/rheumatology/keag320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。